The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

Immune Cells May Lead to More Parkinson's Cases in Men Feb ... 2024 — Researchers have linked disease-related proteins and genes to identify specific cellular pathways responsible for ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter with an ALS advocate, Ben-Noon assembled a team of top scientists to develop ...

Northwestern Medicine scientists have uncovered new insights into how neurofilaments act like Velcro in neurodegenerative ...

For decades, scientists have focused on amyloid plaques—abnormal clumps of misfolded proteins that accumulate between neurons ...

Detailed price information for Meiragtx Holdings Plc (MGTX-Q) from The Globe and Mail including charting and trades.

Plus: Gene therapy with bioengineered blood cells, a possible quantum computing milestone, a new space telescope, how to not ...

Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer’s Disease (AD); ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

Scientists at Scripps Research developed a stable form of carnosic acid, which enhanced memory function and improved ...

Clene (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significant ...

The herb rosemary has long been linked with memory: "There's rosemary, that's for remembrance," says Ophelia in Shakespeare's ...